Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    FP14 - Targeted Therapy - Clinically Focused

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Targeted Therapy - Clinically Focused
    • +

      FP14.06 - Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study

      00:00 - 23:59  |  Presenter: Joshua M. Bauml

      • Abstract

      Loading...

  • +

    P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P75.03 - KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Suman Rao

      • Abstract

      Loading...

  • +

    P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

      00:00 - 00:00  |  Presenter: David R. Spigel

      • Abstract

      Loading...

  • +

    MA03 - New and Revisited Prognostic Factors in Early Stage Lung Cancer

    • 15:30 - 16:30
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Early Stage/Localized Disease
    • +

      MA03.04 - Gender-specific Radiomics Models for Predicting Recurrence in Early Stage (Stage I, II) Non-Small Cell Lung Cancer (ES-NSCLC) Patients

      15:35 - 15:40  |  Presenter: Pranjal Vaidya

      • Abstract

      Loading...

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer

      07:50 - 08:00  |  Presenter: Bob T. Li

      • Abstract

      Loading...

  • +

    ES09 - Biomarkers in Immunotherapy

    • 09:15 - 10:15
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Educational Session
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      ES09.07 - Immunotherapy Biomarkers in NSCLC: Looking into the Future

      09:55 - 10:05  |  Presenter: Vamsidhar Velcheti

      • Abstract

      No abstract available for this presentation

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer

      18:50 - 19:00  |  Presenter: Bob T. Li

      • Abstract

      Loading...

  • +

    MA11 - Expanding Targetable Genetic Alterations in NSCLC

    • 14:15 - 15:15
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      MA11.07 - Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors

      14:35 - 14:40  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...